Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label R-GemOx trial in relapsed or refractory aggressive B-cell lymphomas
2008-007305-36Phase 2Completed
- Sponsor
- GELTAMO
- Start
- Mar 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, gemcitabine, oxaliplatin and dexamethasone in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), sponsored by GELTAMO. Primary endpoints: Overall complete response assessment and Complete response. Started Mar 2009; status: completed.
02
Drugs
rituximabgemcitabineoxaliplatindexamethasone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2008-007305-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007305-36.